%0 Journal Article
%T Bone Loss after Allogeneic Haematopoietic Stem Cell Transplantation: A Pilot Study on the Use of Zoledronic Acid
%A Andreas Hausmann
%A Wolfgang Hill
%A Hans Joachim Stemmler
%A Georg Ledderose
%A Andrea Baur-Melnyk
%A Susanne Fritsch
%A Johanna Ullmann
%A Hans-Jochem Kolb
%A Sandra Geiger
%A Johanna Tischer
%J Chemotherapy Research and Practice
%D 2012
%I Hindawi Publishing Corporation
%R 10.1155/2012/858590
%X Purpose. Bone loss is a common phenomenon following allogeneic haematopoietic stem cell transplantation (allo-HSCT). The study aimed on tolerance and efficacy of zoledronic acid (ZA) in patients after allo-HSCT. Methods. 40 patients’ with osteoporosis or osteopenia were recruited on this phase II study. ZA was given at a dose of 4 mg IV every 3 months for 2 years (yrs). BMD was determined by dual-energy X-ray absorptiometry (LS lumbar spine, FH femur hip). Patients were evaluated for deoxypyridinoline (Dpd) and calcium excretion by longitudinal measurements. Results. 36 patients who had received at least 3 doses of ZA were evaluable. 26 patients had at least two BMD measurements since baseline (BMD group). Among these patients, BMD increased from 0.97¡À0.15 to 1.10¡À0.18 g/cm² (LS baseline—2 yrs, ¦¤
%U http://www.hindawi.com/journals/chrp/2012/858590/